For people with liver cancer, adding vitamin K to their usual treatment (like surgery or a procedure that blocks blood flow to the tumor) does not help them live longer. This holds true regardless of whether they have surgery or the TACE procedure.
See the scientific wording
In patients with hepatocellular carcinoma, adjunctive vitamin K does not significantly improve overall survival in either the surgical or the transarterial chemoembolization (TACE) subgroup, indicating that the lack of survival benefit is consistent across treatment modalities.
Very strong evidence
One moderate-quality study supports this claim, so treat this as an early signal rather than settled science.
What the research says
1 study reviewedSupporting (1)
Systematic Review With Meta-AnalysisMeta-analysis2026
The study looked at whether vitamin K helps liver cancer patients live longer. It found no clear improvement in overall survival, which supports the claim that vitamin K doesn't significantly help survival.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Vitamin K2 is a form of vitamin K that affects liver cancer cells in two ways. It helps stop cancer cells from dividing by slowing down their growth signals, and it also blocks the formation of new blood vessels that the tumor needs to get nutrients. These effects can slow down the cancer and delay its return, but they are not strong enough to kill all cancer cells. The remaining cancer cells can eventually start growing again and spread, leading to death. So despite these helpful effects, vitamin K2 does not significantly extend how long patients live.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
For people with liver cancer, adding vitamin K to their usual treatment (like surgery or a procedure that blocks blood flow to the tumor) does not help them live longer. This holds true regardless of whether they have surgery or the TACE procedure.
Mechanism
1 studyVitamin K2 slows liver cancer by stopping cancer cells from dividing and blocking new blood vessel growth. These effects help delay the cancer's return but do not kill all cancer cells. The remaining cancer cells can start growing again, so patients do not live longer overall.
Vitamin K2 is a form of vitamin K that affects liver cancer cells in two ways. It helps stop cancer cells from dividing by slowing down their growth signals, and it also blocks the formation of new blood vessels that the tumor needs to get nutrients. These effects can slow down the cancer and delay its return, but they are not strong enough to kill all cancer cells. The remaining cancer cells can eventually start growing again and spread, leading to death. So despite these helpful effects, vitamin K2 does not significantly extend how long patients live.
Vitamin K2 inhibits IKK kinase activity, preventing IκB phosphorylation and NF-κB activation, which reduces cyclin D1 expression and downregulates growth factors, slowing tumor cell proliferation.
Vitamin K2 inhibits PKC and PKD1, activating the PKA/p53 pathway, which promotes p21 transcription, causing cell cycle arrest.
Vitamin K2 selectively inhibits VEGFR2 phosphorylation, blocking the angiogenic rebound that occurs after TACE, thereby limiting tumor blood supply.
These anti-tumor effects slow progression and reduce recurrence but do not eliminate all cancer cells. Residual cancer cells can overcome these blocks through alternative pathways or resistance mechanisms, resume growth, and ultimately cause death, so overall survival is not improved.
Evidence from Studies
Supporting (1)
Community contributions welcome
The role of vitamin K in the prognosis of patients with hepatocellular carcinoma: a systematic review and meta-analysis
The study looked at whether vitamin K helps liver cancer patients live longer. It found no clear improvement in overall survival, which supports the claim that vitamin K doesn't significantly help survival.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Randomized Trials Evaluating Adjunctive Vitamin K for Overall Survival in Hepatocellular Carcinoma Patients Undergoing Surgery or TACE
Comprehensive search of databases (e.g., PubMed, Embase, Cochrane) for RCTs comparing standard treatment with vs. without vitamin K in HCC patients. Primary outcome is overall survival, with subgroup analysis by treatment modality (surgery vs. TACE). Inclusion criteria: prospective RCTs, adult human patients, at least 1 year follow-up. Data extraction and meta-analysis using appropriate statistical methods.
Double-Blind Randomized Placebo-Controlled Trial of Vitamin K as Adjunct to Surgery or TACE in Hepatocellular Carcinoma: Impact on Overall Survival
Multicenter, double-blind RCT with 1:1 randomization. Participants: adults with newly diagnosed HCC eligible for surgery or TACE, stratified by treatment modality. Intervention: oral vitamin K (e.g., 45 mg/day) vs. matched placebo for a prespecified duration (e.g., 12 months). Primary outcome: overall survival (time from randomization to death from any cause). Secondary outcomes: progression-free survival, adverse events. Follow-up at least 2 years.
Prospective Cohort Study of Vitamin K Use and Overall Survival in Patients with Hepatocellular Carcinoma Treated with Surgery or TACE
Prospective cohort of consecutive HCC patients undergoing surgery or TACE at multiple centers. Document vitamin K supplementation (yes/no, dose, duration) at baseline. Follow patients for at least 3 years, recording deaths. Use propensity score matching or multivariable Cox regression to adjust for confounders (age, liver function, tumor stage, comorbidities). Primary outcome: overall survival.
Retrospective Case-Control Study of Vitamin K Exposure in Hepatocellular Carcinoma Patients: Comparison of Survivors and Non-Survivors
Select cases: HCC patients who died within 2 years of treatment (surgery/TACE). Controls: HCC patients who survived at least 5 years. Match on age, sex, stage, and treatment. Data on vitamin K use collected from medical records or interviews. Calculate odds ratios for vitamin K exposure. Ensure adequate sample size (e.g., 200 cases, 400 controls).